Evidence map›Paper›PMID 36750252›Full record

ArticleJournal for immunotherapy of cancer2023

Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis.

Bayli DiVita Dean, Tyler Wildes, Joseph Dean, Oleg Yegorov, Changlin Yang, David Shin, Connor Francis, John W Figg, Mathew Sebastian, Laura Falceto Font and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 citations in OpenAlex.

  1. Rewriting microenvironment immunity in glioblastoma.Molecular therapy. Oncology · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Bayli DiVita Dean *Lillian S Wells Department of Neurosurgery, University of Florida, Gainesville, Florida, USA.ORCID 0000-0002-5236-2500
Tyler Wildes *Lillian S Wells Department of Neurosurgery, University of Florida, Gainesville, Florida, USA.
Joseph DeanDepartment of Infectious Diseases and Immunology, University of Florida, Gainesville, Florida, USA.
Oleg YegorovLillian S Wells Department of Neurosurgery, University of Florida, Gainesville, Florida, USA.
Changlin YangLillian S Wells Department of Neurosurgery, University of Florida, Gainesville, Florida, USA.
David ShinLillian S Wells Department of Neurosurgery, University of Florida, Gainesville, Florida, USA.
Connor FrancisLillian S Wells Department of Neurosurgery, University of Florida, Gainesville, Florida, USA.
John W FiggLillian S Wells Department of Neurosurgery, University of Florida, Gainesville, Florida, USA.
Mathew SebastianLillian S Wells Department of Neurosurgery, University of Florida, Gainesville, Florida, USA.ORCID 0000-0002-1058-1676
Laura Falceto FontLillian S Wells Department of Neurosurgery, University of Florida, Gainesville, Florida, USA.
Dan JinLillian S Wells Department of Neurosurgery, University of Florida, Gainesville, Florida, USA.
Alexandra ReidLillian S Wells Department of Neurosurgery, University of Florida, Gainesville, Florida, USA.
Ginger MooreLillian S Wells Department of Neurosurgery, University of Florida, Gainesville, Florida, USA.
Brandon FernandezLillian S Wells Department of Neurosurgery, University of Florida, Gainesville, Florida, USA.
Brandon WummerLillian S Wells Department of Neurosurgery, University of Florida, Gainesville, Florida, USA.
Carmelle KuizonLillian S Wells Department of Neurosurgery, University of Florida, Gainesville, Florida, USA.
Duane MitchellLillian S Wells Department of Neurosurgery, University of Florida, Gainesville, Florida, USA.
Catherine T FloresLillian S Wells Department of Neurosurgery, University of Florida, Gainesville, Florida, USA catherine.flores@neurosurgery.ufl.edu.
University of Florida · US

Funding

Hematopoietic stem cells overcome treatment resistance to adoptive cellular therapy against malignant gliomasR01NS112315 · NINDS · UNIVERSITY OF FLORIDA · PI FLORES, CATHERINE T · 2019 to 2023
$1.7M
Hematopoietic stem cells overcome treatment resistance to PD-1 blockade against brain tumorsR01NS111033 · NINDS · UNIVERSITY OF FLORIDA · PI FLORES, CATHERINE T · 2020 to 2024
$1.7M
Team-based Interdisciplinary Cancer Research Training ProgramT32CA257923 · NCI · UNIVERSITY OF FLORIDA · PI SIEMANN, DIETMAR W · 2021 to 2025
$1.2M
NCI NIH HHS T32 CA257923NINDS NIH HHS R01 NS111033NINDS NIH HHS R01 NS112315
6 · The paper itself

Abstract

backgroundGlioma-induced immune dysregulation of the hematopoietic system has been described in a limited number of studies. In this study, our group further demonstrates that gliomas interrupt the cellular differentiation programming and outcomes of hematopoietic stem and progenitor cells (HSPCs) in the bone marrow. HSPCs from glioma-bearing mice are reprogrammed and driven towards expansion of myeloid lineage precursors and myeloid-derived suppressor cells (MDSCs) in secondary lymphoid organs. However, we found this expansion is reversed by immunotherapy. Adoptive cellular therapy (ACT) has been demonstrably efficacious in multiple preclinical models of central nervous system (CNS) malignancies, and here we describe how glioma-induced dysfunction is reversed by this immunotherapeutic platform.

methodsThe impact of orthotopic KR158B-luc glioma on HSPCs was evaluated in an unbiased fashion using single cell RNAseq (scRNAseq) of lineage

resultsUsing scRNAseq, we observed an altered HSPC landscape in glioma-bearing versus non-tumor-bearing mice . In addition, an expansion of myeloid lineage subsets, including granulocyte macrophage precursors (GMPs) and MDSCs, were observed in glioma-bearing mice relative to non-tumor-bearing controls. Furthermore, MDSCs from glioma-bearing mice demonstrated increased suppressive capacity toward tumor-specific T cells as compared with MDSCs from non-tumor-bearing hosts. Interestingly, treatment with ACT overcame these suppressive properties. When HSPCs from glioma-bearing mice were transferred in the context of ACT, we observed significant survival benefit and long-term cures in orthotopic glioma models compared with mice treated with ACT using non-glioma-bearing HSPCs.

Indexed as

Central Nervous System NeoplasmsGliomaAnimalsCell Line, TumorHematopoietic Stem CellsImmunotherapyMiceT-Lymphocytesdendritic cellsimmunotherapymyeloid-derived suppressor cells

Identifiers

PMID36750252
PMCPMC9906384
OpenAlexW4319345027

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.